Piper Sandler raises Ryan Specialty target to $44

1 min read | Published on 09 Jul 2026, 12:44 AM |Updated on 15 Jul 2026, 06:35 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Five analysts updated price targets for Ryan Specialty Holdings, with Piper Sandler raising its target to $44 while maintaining a Neutral rating. KBW set the highest target at $48 with an Outperform rating, while Cantor Fitzgerald, Wells Fargo, and JP Morgan also adjusted their targets.

*this image is generated using AI for illustrative purposes only.

Ryan Specialty Holdings has received updated price targets from five analysts, reflecting revised outlooks on the insurance brokerage firm's stock performance. Piper Sandler analyst Paul Newsome maintained a Neutral rating and raised the price target to $44 from $40. Keefe, Bruyette & Woods (KBW) analyst Meyer Shields maintained an Outperform rating and raised the price target to $48 from $44. Separately, Cantor Fitzgerald analyst Ryan Tunis maintained a Neutral rating while increasing the price target to $34 from $33. Additionally, Wells Fargo analyst Elyse Greenspan maintained an Equal-Weight rating and raised the price target to $39 from $31. JP Morgan analyst Pablo Singzon maintained an Underweight rating and raised the price target to $39 from $37.

Rating and Price Target Details

The adjustments from all five firms indicate a reassessment of the company's valuation and potential upside. Piper Sandler's increase to $44 accompanies its Neutral stance. KBW's higher target of $48 suggests confidence in growth, whereas Cantor Fitzgerald's more conservative increase to $34 aligns with its Neutral rating. Wells Fargo's increase to $39 reflects a revised outlook under its Equal-Weight rating. JP Morgan's increase to $39 accompanies its Underweight rating.

Firm	Analyst	Rating	Previous Price Target	New Price Target
Piper Sandler	Paul Newsome	Neutral	$40	$44
Keefe, Bruyette & Woods	Meyer Shields	Outperform	$44	$48
Cantor Fitzgerald	Ryan Tunis	Neutral	$33	$34
Wells Fargo	Elyse Greenspan	Equal-Weight	$31	$39
JP Morgan	Pablo Singzon	Underweight	$37	$39

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific factors are driving the consensus among analysts to raise price targets despite varying ratings?

How might Ryan Specialty's recent performance influence future analyst ratings and price targets?

What potential market conditions could lead to further upward revisions of price targets?

Morgan Stanley raises Ryan Specialty target to $42

0 min read | Published on 01 Jul 2026, 06:21 PM |Updated on 06 Jul 2026, 10:42 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Morgan Stanley analyst Bob Huang maintained an Overweight rating on Ryan Specialty Holdings and raised the price target to $42 from $39. Separately, Goldman Sachs analyst Robert Cox maintained a Neutral rating with a price target of $40, up from $35.

*this image is generated using AI for illustrative purposes only.

Morgan Stanley analyst Bob Huang has maintained an Overweight rating on Ryan Specialty Holdings while raising the price target to $42 from $39. This revised target reflects an updated valuation for the NYSE-listed specialty insurance firm. Separately, Goldman Sachs analyst Robert Cox maintained a Neutral rating on the stock with a price target of $40, up from a previous $35.

Rating and Price Action

The research note from Morgan Stanley reaffirms the Overweight stance, suggesting the stock offers potential upside relative to its sector peers. The price target increase to $42 implies confidence in the firm's fundamentals and market conditions.